Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

GLUE

Monte Rosa Therapeutics Inc

May 17 • 04:00PM ET

5.20

Dollar change -0.02
Percentage change -0.38	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VHT VTWO IWC CNCR AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.53	Insider Own	36.88%	Shs Outstand	50.14M	Perf Week	7.22%
Market Cap	262.65M	Forward P/E	-	EPS next Y	-2.13	Insider Trans	0.00%	Shs Float	31.88M	Perf Month	-12.16%
Income	-135.28M	PEG	-	EPS next Q	-0.57	Inst Own	63.82%	Short Float	6.01%	Perf Quarter	-12.75%
Sales	1.06M	P/S	247.78	EPS this Y	16.02%	Inst Trans	1.00%	Short Ratio	12.28	Perf Half Y	41.30%
Book/sh	3.04	P/B	1.71	EPS next Y	3.35%	ROA	-46.99%	Short Interest	1.91M	Perf Year	-7.96%
Cash/sh	3.82	P/C	1.36	EPS next 5Y	-	ROE	-68.28%	52W Range	2.44 - 8.84	Perf YTD	-7.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-96.71%	ROI	-69.61%	52W High	-41.18%	Beta	1.50
Dividend TTM	-	Quick Ratio	4.82	Sales past 5Y	0.00%	Gross Margin	-554.89%	52W Low	113.11%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	4.82	EPS Y/Y TTM	-3.99%	Oper. Margin	-13533.74%	RSI (14)	41.87	Volatility	8.80% 8.23%
Employees	133	Debt/Eq	0.30	Sales Y/Y TTM	-	Profit Margin	-12714.47%	Recom	1.00	Target Price	15.43
Option/Short	Yes / Yes	LT Debt/Eq	0.27	EPS Q/Q	18.15%	Payout	-	Rel Volume	0.98	Prev Close	5.22
Sales Surprise	-23.84%	EPS Surprise	9.28%	Sales Q/Q	-	Earnings	May 09 BMO	Avg Volume	155.95K	Price	5.20
SMA20	-4.05%	SMA50	-17.13%	SMA200	-3.17%	Trades		Volume	153,345	Change	-0.38%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	Wedbush	Outperform	$11
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$18
Oct-13-22	Initiated	UBS	Buy	$22
Aug-15-22	Initiated	Jefferies	Buy	$20
Apr-28-22	Initiated	Credit Suisse	Neutral	$19
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$19
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20

May-16-24 01:09PM	Monte Rosa Therapeutics Prices $100 Million Public Offering (MT Newswires)
07:00AM	Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering (GlobeNewswire)
May-15-24 04:01PM	Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-10-24 03:26PM	Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview (GuruFocus.com) -6.37%
May-09-24 01:55PM	GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:21AM	Loading…
07:21AM	Monte Rosa Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-24 04:01PM	Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer (GlobeNewswire) -5.72%
Apr-29-24 10:36AM	UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating (MT Newswires) +5.25%
Apr-10-24 08:50AM	Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why (Zacks) -8.78%
Apr-04-24 09:55AM	Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect? (Zacks)
Mar-22-24 08:50AM	Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-19-24 09:55AM	Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know (Zacks)
Mar-16-24 05:31AM	Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
Mar-14-24 01:53PM	GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -8.42%
07:22AM	Loading…
07:22AM	Monte Rosa Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-11-24 07:00AM	Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1 Pathway Inhibitor (GlobeNewswire)
Jan-31-24 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-16-24 09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool) -8.42%
Jan-08-24 07:15AM	Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 (GlobeNewswire) +14.39%
Jan-03-24 07:00AM	Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-21-23 07:00AM	Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference (GlobeNewswire) -8.31%
Nov-09-23 08:10AM	Monte Rosa Therapeutics Inc (GLUE) Reports Q3 2023 Financial Results and Strategic Developments (GuruFocus.com) -10.57%
07:10AM	Monte Rosa Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-23 10:00AM	Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases (GlobeNewswire) +6.93%
Oct-27-23 07:00AM	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.20%
Oct-26-23 04:30PM	Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-24-23 09:35AM	Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE) (Zacks)
08:03AM	Loading…
Oct-17-23 08:03AM	Roche is stuck on molecular glue (BioPharma Dive) -19.80%
07:00AM	Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases (GlobeNewswire)
07:00AM	Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors (GlobeNewswire)
Aug-10-23 07:27AM	Monte Rosa Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:15AM	Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-26-23 07:30AM	Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors (GlobeNewswire)
Jul-16-23 09:50AM	We're Keeping An Eye On Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate (Simply Wall St.)
May-30-23 04:30PM	Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences (GlobeNewswire) +5.16%
May-23-23 07:30AM	Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases (GlobeNewswire)
May-11-23 07:50AM	Monte Rosa Therapeutics: Q1 Earnings Snapshot (AP Finance)
07:30AM	Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-17-23 04:30PM	Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023 (GlobeNewswire)
Mar-23-23 07:30AM	Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors (GlobeNewswire)
Mar-16-23 07:52AM	Monte Rosa Therapeutics: Q4 Earnings Snapshot (AP Finance) +7.35%
07:30AM	Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-06-23 08:30AM	Here's Why We're Not Too Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation (Simply Wall St.) -6.94%
Feb-03-23 07:30AM	Monte Rosa Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +15.15%
Jan-25-23 09:55AM	How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46% (Zacks)
Jan-09-23 07:30AM	Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023 (GlobeNewswire) -14.32%
Jan-04-23 07:30AM	Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-17-22 01:58PM	Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies (Insider Monkey)
Nov-10-22 07:30AM	Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +5.26%
Nov-01-22 07:30AM	Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors (GlobeNewswire)
Oct-31-22 04:30PM	Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) +5.99%
Oct-20-22 04:30PM	Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium (GlobeNewswire)
Sep-06-22 07:30AM	Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader (GlobeNewswire)
Aug-30-22 08:35AM	We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate (Simply Wall St.) -10.32%
Aug-11-22 07:30AM	Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +5.17%
Jun-14-22 05:16AM	Upcoming 220K-square-foot South End lab project almost fully leased (American City Business Journals) +5.08%
May-11-22 07:30AM	Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -16.03%
Apr-08-22 01:00PM	Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022 (GlobeNewswire)
Mar-29-22 07:30AM	Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates (GlobeNewswire) +16.33%
Mar-23-22 11:32AM	We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth (Simply Wall St.)
Feb-03-22 04:30PM	Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -5.58%
Jan-25-22 07:30AM	Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders (GlobeNewswire) -9.86%
Jan-04-22 07:30AM	Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-21 07:30AM	Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer (GlobeNewswire)
Nov-22-21 07:30AM	Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-10-21 07:30AM	Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Nov-08-21 07:00AM	Merck KGaA veteran helms immuno-oncology startup with $80M (American City Business Journals)
Oct-20-21 07:30AM	Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit (GlobeNewswire) +5.45%
Oct-07-21 09:00AM	Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer (GlobeNewswire)
Sep-30-21 04:30PM	Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference (GlobeNewswire)
Sep-24-21 08:49AM	Here's Why We're Not At All Concerned With Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation (Simply Wall St.)
Sep-10-21 07:30AM	Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Sep-08-21 07:30AM	Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire) -13.53%
Aug-12-21 07:30AM	Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress (GlobeNewswire)

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GLUE

Monte Rosa Therapeutics Inc

Upgrade your FINVIZ experience